Business · 30/12/2024Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on Withdrawal of 23 Abbreviated New Drug Applications
Summary
The FDA is correcting a notice that announced the withdrawal of approval of 23 abbreviated new drug applications, including those for tolmetin sodium capsules and citalopram hydrobromide tablets, as of August 28, 2024, from applicants including Fosun Pharma USA Inc.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →